BRAF and melanoma: Recommendation 8: Molecular testing to detect mutations in the BRAF gene is recommended in the scenario of patients with high-risk stage II, 3 and 4 melanoma, using a sample with adequate neoplastic representation and a molecular technique duly validated by the laboratory.